(R)-2-chloro-1-(2-furyl)ethanol | 769140-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (R)-2-chloro-1-(2-furyl)ethanol
• 英文别名: (R)-2-(1-hydroxy-2-chloroethyl)-furan；(R)-2-chloro-1-(furan-2-yl)ethan-1-ol；R-1-(2-furyl)-2-chloroethanol；(1R)-2-chloro-1-(furan-2-yl)ethanol
• CAS: 769140-91-2
• 化学式: C₆H₇ClO₂
• 分子量: 146.573
• InChiKey: YUBBGHLHXUVOHT-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-2-chloro-1-(2-furyl)ethanol 在 氢氧化钾 、 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 3.25h， 生成 (S)-1-(2-furyl)-2-(methylamino)ethanol
  参考文献：
  名称：

  Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols

  摘要：

  As part of medicinal chemistry efforts we found it necessary to develop general syntheses of highly enantiomerically enriched 1-aryl-2-chloroethanols and 1-aryl-2-methylaminoethanols. A survey of literature methods suggested that a truly general approach had not yet been reported, encouraging us to undertake the development of such a methodology. This study describes the design, development, and reduction to practice of a general synthesis of chiral 1-aryl-2-chloroethanols and the transformation of these entities to highly enantiomerically enriched 1-aryl-2-methylaminoethanols. Of particular importance were observations of the impact of solvent and the method of catalyst preparation on the yield and enantiomerical excess of chlorohydrins prepared via Noyori transfer hydrogenations of aryl-chloromethyl ketones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.017
• 作为产物：
  描述：

  [[2-chloro-1-(2-furyl)ethenyl]oxy]tri-isopropylsilane 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 (1S,2S)-(+)-N-对甲苯磺酰基-1,2-二苯基乙二胺 甲酸 、 氢氟酸 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.5h， 生成 (R)-2-chloro-1-(2-furyl)ethanol
  参考文献：
  名称：

  Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols

  摘要：

  As part of medicinal chemistry efforts we found it necessary to develop general syntheses of highly enantiomerically enriched 1-aryl-2-chloroethanols and 1-aryl-2-methylaminoethanols. A survey of literature methods suggested that a truly general approach had not yet been reported, encouraging us to undertake the development of such a methodology. This study describes the design, development, and reduction to practice of a general synthesis of chiral 1-aryl-2-chloroethanols and the transformation of these entities to highly enantiomerically enriched 1-aryl-2-methylaminoethanols. Of particular importance were observations of the impact of solvent and the method of catalyst preparation on the yield and enantiomerical excess of chlorohydrins prepared via Noyori transfer hydrogenations of aryl-chloromethyl ketones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.017

文献信息

• [EN] PROCESS TO PRODUCE ENANTIOMERICALLY ENRICHED 1-ARYL- AND 1-HETEROARYL-2-AMINOETHANOLS<br/>[FR] PROCEDE DE PREPARATION D'1-ARYL- ET D'1-HETEROARYL-2-AMINOETHANOLS ENRICHIS EN ENANTIOMERES
  申请人：UPJOHN CO

  公开号：WO2004085414A1

  公开（公告）日：2004-10-07

  The invention relates to a method of preparing enantiomerically enriched amino alcohols of Formula (I) wherein the variable R1, R2, and R3 are defined herein.

  这项发明涉及一种制备式(I)的对映体富集氨基醇的方法，其中变量R1、R2和R3在此处被定义。
• Process to produce enantiomerically enriched 1-aryl-and 1-heteroaryl-2-aminoethanols
  申请人：Pfizer, Inc.

  公开号：US20040236151A1

  公开（公告）日：2004-11-25

  The invention relates to a method of preparing enantiomerically enriched amino alcohols of Formula I 1 wherein the variable R1, R2, and R3 are defined herein.

  本发明涉及一种制备对映体富集的式I1的氨基醇的方法，其中变量R1、R2和R3在此处定义。
• The Ir-Catalyzed Asymmetric Hydrogenation of α-Halogenated Ketones Utilizing Cinchona-Alkaloid-Derived NNP Ligand to Produce (<i>R</i>)- and (<i>S</i>)-Halohydrins
  作者：Qian Chen、Hao Sun、Linlin Li、Jie Tian、Qian Xu、Nana Ma、Li Li、Lin Zhang、Chun Li

  DOI：10.1021/acs.joc.2c02109

  日期：2022.12.2

  hydrogenation of α-halogenated ketones with iridium catalyst was developed, utilizing easily accessed cinchona-alkaloid-based NNP ligands. Various α-chloroacetophenones, heterocyclic thienyl and furanyl substrates, and even bromoketones were completely converted to the desired chiral halohydrins by this protocol. Both (R)- and (S)-chiral halohydrins can be prepared by changing the configurations of the chiral

  利用易于获取的基于金鸡纳生物碱的 NNP 配体，开发了铱催化剂对 α-卤化酮的不对称氢化。通过该协议，各种 α-氯苯乙酮、杂环噻吩基和呋喃基底物，甚至溴酮完全转化为所需的手性卤代醇。( R )- 和 ( S )- 手性卤代醇都可以通过改变手性配体 NNP 的构型来制备，分别具有高达 99.6% ee（对映体过量）和 98.8% ee。此外，有效地进行了克级实验。
• Tandem Concurrent Processes: One-Pot Single-Catalyst Biohydrogen Transfer for the Simultaneous Preparation of Enantiopure Secondary Alcohols
  作者：Fabricio R. Bisogno、Iván Lavandera、Wolfgang Kroutil、Vicente Gotor

  DOI：10.1021/jo802350f

  日期：2009.2.20

  A novel one-pot tandem biohydrogen transfer process to concurrently obtain two enantiopure sec-alcohols is presented; thus, using a suitable single enzyme and a catalytic amount of cofactor, several interesting building blocks could be easily achieved in an enantiocomplementary fashion, minimizing dramatically the quantity of reagents usually employed in the "coupled-substrate" approach.
• Chemoenzymatic synthesis of both enantiomers of 2-chloro-1-(2-furyl)ethanol
  作者：Zuhal Gercek、Devrim Karakaya、Ayhan S. Demir

  DOI：10.1016/j.tetasy.2005.04.007

  日期：2005.5

  Enzyme catalyzed transesterification of rac-2-chloro-1-(2-furyl)ethanol rac-1 using vinyl acetate afforded the enantiomers of 2-chloro-1-(2-furyl)ethanol 1 and 2-chloro-1-(2-furyl)ethyl acetate 2 in high enantiomeric excess. Several lipases were used for the kinetic resolution of racemic 2-chloro-1-(2-furyl)ethanol 1, in which the lipases from Pseudomonas cepacia, Candida antarctica and Candida cylindracea displayed high enantioselectivity towards 1. (C) 2005 Elsevier Ltd. All rights reserved.